About Neurona Therapeutics
Neurona Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2008 by Cory R. Nicholas, and was acquired by UCB in April 2026. Cell-based therapies are developed for intractable neurological diseases. Neurona Therapeutics has raised $417.69 million across 9 funding rounds from investors including Fidelity Investments, ARE and UCB. The company has 67 employees. Its chief executive, as recorded, is Cory R. Nicholas. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Its legal entity is NEURONA THERAPEUTICS, INC. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.
- Headquarters San Francisco, United States
- Employees 67
- Founders Cory R. Nicholas
- Stage Acquired
- SectorsHealthcare
- Website neuronatherapeutics.com
- Social LinkedIn
- Acquired by UCB (Apr 2026)
- Legal Name Neurona Therapeutics, Inc.
- Total Equity Funding$417.69M (USD)
in 9 rounds
- Latest Funding Round$102M (USD), Series E
Mar 2025
- InvestorsFidelity Investments
& 15 more
- Employee Count67
- Acquired byUCB
(Apr 2026)
Funding Insights of Neurona Therapeutics
Neurona Therapeutics has successfully raised a total of $417.69M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $102 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $417.69M
- Total Rounds 9
- Last Round Series E — $102M
- First Round $95,000
(Aug 2008)
- Investors Count 15
All 9 funding rounds of Neurona Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2025 | $102M | Series E | – | – | |
| Feb 2024 | $120M | Series E | – | Viking Global Investors, Cormorant Asset Management | |
| Dec 2022 | $72.01M | Series D | – | – | – |
| Jun 2021 | $41.5M | Series C | – | UCB Ventures | |
| Mar 2021 | $28.33M | Series C | – | – | – |
| Nov 2019 | $15.03M | Series B | – | – | – |
| Feb 2018 | $10.04M | Series A | – | – | – |
| Dec 2016 | $28.68M | Series A | – | TCG | – |
| Aug 2008 | $95,000 | Seed | – | – | – |
16 investors in total: 16 institutional.
Investors in Neurona Therapeutics
Neurona Therapeutics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, ARE and UCB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
| soleuscapital.com | ||||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Philanthropic assets are managed by Willett Advisors LLC. | willettadvisors.com | New York, United States | ||
Ysios Capital is recognized as a leading life sciences investor. | ysioscapital.com | Barcelona, Spain | ||
LYFE Capital is recognized as a premier healthcare investment platform. | lyfecapital.com | Menlo Park, USA | ||
Seed to growth stage US tech startups are invested in. | ironfireventures.com | San Francisco, United States | ||
Investments in healthcare companies are made by SymBiosis. | symbiosis.vc | Bentonville, United States | ||
UCB Ventures is focused on strategic corporate venture investments. | 2017 | ucbventures.com | Brussels, Belgium | |
Multiple sectors are invested in by this single-family office. | euclideancapital.tcc.mode | New York, United States |
Investor details for Neurona Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neurona Therapeutics
46 people are tracked at Neurona Therapeutics (17 in leadership, 9 in board & advisors, 20 in team); the tracked headcount is 67.
| Name | Role | Group |
|---|---|---|
Cory R. Nicholas | Co-Founder & CEO | Leadership |
Catherine Priest | Chief Development Officer | Leadership |
Gautam Banik | Chief Technology Officer | Leadership |
David Blum | Chief Medical Officer | Leadership |
Michael Watson, PhD | Associate Director, Assay Development and Quality Control | Leadership |
Sergei Shevchuk | Senior Director of Quality Assurance & Quality Control | Leadership |
James Stutz | CFO & CBO | Leadership |
James Tanaka | Senior Director of Finance | Leadership |
Yves MAURY | Director, Discovery Department | Leadership |
Alessandro Bulfone | VP of Operations | Leadership |
Steven Havlicek | Associate Research Director | Leadership |
Hongjun(Robin) Zhou | Associate Director, Bioinformatics | Leadership |
Melvin Abara | Director Of Quality Assurance | Leadership |
Nadia Agopyan | Senior Vice President | Leadership |
Seonok Lee, Ph.D. | Director | Leadership |
Sheri Madrid | VP of Clinical Operations & Development | Leadership |
Agape Eleftheriadis | Vice President Human Resources | Leadership |
Leo Guthart | Board Member | Board & advisors |
Erica Whittaker | Board Member | Board & advisors |
Arnold Kriegstein | Advisor | Board & advisors |
26 more people are available in the full profile.
Complete people profiles for Neurona Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neurona Therapeutics
4 dated milestones of Neurona Therapeutics across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Neurona Therapeutics is founded.
- Funding First funding round of $95K.
- Funding Latest funding round, Series E, of $102.0M.
- Exit Acquired by UCB.
Competitors of Neurona Therapeutics
Neurona Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Neurona Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neurona Therapeutics
The website of Neurona Therapeutics (neuronatherapeutics.com) receives about 9.4K visits a month.
- Monthly visits9.4K
▲ 83.4% vs previous month
Websites whose visitors overlap most with Neurona Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| r2mpharma.com | 100% | 2.9K | #4,331,217 | View details |
Top companies in Cell Therapy
3 companies that operate in the same segment as Neurona Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurona Therapeutics
Complete news archive for Neurona Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurona Therapeutics
Neurona Therapeutics was founded in 2008.
Neurona Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Cory R. Nicholas is the CEO of Neurona Therapeutics, as recorded in our data. They have also founded this company.
Neurona Therapeutics is a funded company, having raised a total of $417.69M across 9 funding rounds to date. The company's 1st funding round was a Seed of $95K, raised on Aug 2008.
Neurona Therapeutics has 67 employees.
Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.
Neurona Therapeutics's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Neurona Therapeutics has 16 investors. Key investors include Fidelity Investments, ARE, UCB, Schroders, and The Column Group.
Neurona Therapeutics operates through Neurona Therapeutics, Inc..
Yes. Neurona Therapeutics was acquired by UCB in April 2026.